Analysts Set Teleflex Incorporated (NYSE:TFX) PT at $141.57

Key Points

• Teleflex Incorporated has received an average recommendation of "Hold" from ten research firms, with one sell rating, eight holds, and one buy rating.
• The company reported a Q2 EPS of $3.73, surpassing expectations of $3.36, and had a revenue of $780.9 million, which also exceeded estimates.
• Teleflex declared a quarterly dividend of $0.34 per share, reflecting a 1.2% dividend yield and a payout ratio of 32%.

Teleflex Incorporated (NYSE:TFX - Get Free Report) has received an average recommendation of "Hold" from the ten brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $141.5714.

TFX has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Teleflex from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 2nd. Morgan Stanley cut their price objective on shares of Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a report on Monday, May 5th. Wells Fargo & Company cut their price objective on shares of Teleflex from $137.00 to $131.00 and set an "equal weight" rating on the stock in a report on Friday, August 1st. Mizuho increased their price target on shares of Teleflex from $130.00 to $135.00 and gave the stock a "neutral" rating in a report on Friday, August 1st. Finally, Royal Bank Of Canada increased their price target on shares of Teleflex from $130.00 to $135.00 and gave the stock a "sector perform" rating in a report on Friday, August 1st.

Insiders Place Their Bets

In related news, Director Andrew A. Krakauer acquired 1,000 shares of the stock in a transaction on Tuesday, August 5th. The shares were acquired at an average price of $115.25 per share, for a total transaction of $115,250.00. Following the transaction, the director owned 7,192 shares in the company, valued at approximately $828,878. This trade represents a 16.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stuart A. Randle acquired 1,000 shares of the stock in a transaction on Tuesday, August 5th. The stock was bought at an average price of $115.86 per share, for a total transaction of $115,860.00. Following the transaction, the director owned 7,547 shares in the company, valued at approximately $874,395.42. This represents a 15.27% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 5,500 shares of company stock worth $633,590. Corporate insiders own 1.40% of the company's stock.

Institutional Investors Weigh In On Teleflex

Hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas purchased a new stake in Teleflex in the 1st quarter worth approximately $1,242,000. Amalgamated Bank boosted its position in Teleflex by 56.9% in the 1st quarter. Amalgamated Bank now owns 14,046 shares of the medical technology company's stock worth $1,941,000 after purchasing an additional 5,095 shares in the last quarter. New York State Teachers Retirement System lifted its position in shares of Teleflex by 13.9% during the 1st quarter. New York State Teachers Retirement System now owns 45,063 shares of the medical technology company's stock valued at $6,227,000 after buying an additional 5,482 shares in the last quarter. Brown Advisory Inc. lifted its position in shares of Teleflex by 34.2% during the 1st quarter. Brown Advisory Inc. now owns 2,524 shares of the medical technology company's stock valued at $349,000 after buying an additional 643 shares in the last quarter. Finally, CX Institutional purchased a new position in shares of Teleflex during the 1st quarter valued at approximately $105,000. Hedge funds and other institutional investors own 95.62% of the company's stock.

Teleflex Stock Up 2.7%

Teleflex stock traded up $3.08 during trading hours on Thursday, reaching $118.57. The stock had a trading volume of 701,177 shares, compared to its average volume of 582,619. The company has a market cap of $5.24 billion, a price-to-earnings ratio of 27.90, a PEG ratio of 1.65 and a beta of 1.08. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44. The business's 50 day moving average price is $118.09 and its 200-day moving average price is $134.60. Teleflex has a 52 week low of $108.90 and a 52 week high of $249.90.

Teleflex (NYSE:TFX - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.36 by $0.37. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The firm had revenue of $780.90 million for the quarter, compared to the consensus estimate of $771.53 million. During the same quarter in the prior year, the company posted $3.42 earnings per share. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. Sell-side analysts anticipate that Teleflex will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 15th. Shareholders of record on Friday, August 15th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 1.1%. The ex-dividend date is Friday, August 15th. Teleflex's dividend payout ratio is currently 32.00%.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.